ESH Position Paper: Renal denervation-an interventional therapy of resistant hypertension

Journal of Hypertension

Volumn 30, Issue 5, 2012, Pages 837-841

  Schmieder, Roland E ^a   Redon, Josep ^b   Grassi, Guido ^c,j   Kjeldsen, Sverre E ^d   Mancia, Giuseppe ^c   Narkiewicz, Krzysztof ^e   Parati, Gianfranco ^f   Ruilope, Luis ^g   Van De Borne, Philippe ^h   Tsioufis, Costas ⁱ  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF VALENCIA   (Spain)

^c SAN GERARDO HOSPITAL   (Italy)

^d UNIVERSITY OF OSLO   (Norway)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^h ERASME HOSPITAL   (Belgium)

ⁱ UNIVERSITY OF ATHENS   (Greece)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

more..

Author keywords

European Society of Hypertension; interventional therapy; resistant hypertension

Indexed keywords

ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 84859898722     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328352ce78     Document Type: Article

References (44)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223. (Pubitemid 40138015)
2. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121-1123. (Pubitemid 351731743)
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913. (Pubitemid 35472129)
4. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of bloodpressure-related disease, 2001. Lancet 2008; 371:1513-1518. (Pubitemid 351626187)
5. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
7. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target<140mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial, Eur Heart J,2011, 32,1500-1508.
8. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al.The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials.J Hypertens2011;29:4-16.
9. Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens 2011; 29:1641-1648.
10. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
11. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
12. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046-1058.
13. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063-2070. (Pubitemid 33035812)
14. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54:1195-1201.
15. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
16. Simplicity HTN-1 Investigators 2011. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911-917.
17. Simplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
18. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009; 54:690-697.
19. Grassi G, Seravalle G, Bertinieri G, Turri C, Dell'Oro R, Stella ML, et al. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens 2000; 18:587-593. (Pubitemid 30303490)
20. Flaa A, Eide IK, Kjeldsen SE, Rostrup M. Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year followup study. Hypertension 2008; 52:336-341.
21. Grassi G, Seravalle G, Trevano FQ, Dell'oro R, Bolla G, Cuspidi C, et al. Neurogenic abnormalities in masked hypertension. Hypertension 2007; 50:537-542. (Pubitemid 47312241)
22. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008; 52:925-931.
23. Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE. Preeclampsia: a state of sympathetic overactivity. N Engl J Med 1996; 335:1480-1485.
24. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20:933-939.
25. Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens 2011; 2011:642416.
26. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A 1989; 11 (Suppl 1):75-89. (Pubitemid 19159111)
27. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1989; 14:177-183.
28. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31:68-72. (Pubitemid 28124694)
29. Barajas L, Liu L, Powers K. Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol 1992; 70:735-749.
30. Luff SE, Hengstberger SG, McLachlan EM, Anderson WP. Distribution of sympathetic neuroeffector junctions in the juxtaglomerular region of the rabbit kidney. J Auton Nerv Syst 1992; 40:239-253.
31. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298:R245-R253.
32. Ditting T, Freisinger W, Siegel K, Fiedler C, Small L, Neuhuber W, et al. Tonic postganglionic sympathetic inhibition induced by afferent renal nerves? Hypertension 2012; 59:467-476.
33. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev 1991; 71:659-682.
34. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979. (Pubitemid 35176304)
35. Calaresu FR, Stella A, Zanchetti A. Haemodynamic responses and renin release during stimulation of afferent renal nerves in the cat. J Physiol 1976; 255:687-700.
36. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197. (Pubitemid 27069290)
37. Doumas M, Papademetriou V, Douma S, Faselis C, Tsioufis K, Gkaliagkousi E, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens 2010; 2011:318549.
38. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1266 cases. JAMA 1953; 152:1501-1504.
39. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 2011; 58:1176-1182.
40. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, et al. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond) 1994; 87:13-20. (Pubitemid 24220266)
41. Gazdar AF, Dammin GJ. Neural degeneration and regeneration in human renal transplants. N Engl J Med 1970; 283:222-224.
42. Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients (ARSENAL). ClinicalTrialsgov.NCT01438229.
43. Banegas JR, Messerli FH, Waeber B, Rodriguez-Artalejo F, de la Sierra A, Segura J, et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med 2009; 122:1136-1141.
44. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069-1075.